Patterns of major cutaneous surgeries and reconstructions in patients with cutaneous squamous cell carcinoma in the USA.
| Autor: | Chen CI; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Jalbert JJ; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Wu N; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Ruiz ES; Department of Dermatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Future oncology (London, England) [Future Oncol] 2024 Apr; Vol. 20 (11), pp. 691-701. Date of Electronic Publication: 2023 Nov 23. |
| DOI: | 10.2217/fon-2023-0389 |
| Abstrakt: | Aim: Since use of major cutaneous surgeries/reconstructions among patients with cutaneous squamous cell carcinoma (CSCC) is not well described, we sought to quantify major cutaneous surgeries/reconstructions among patients with CSCC who were newly diagnosed and for those treated with systemic therapy, stratified by immune status. Methods: We used the Optum ® Clinformatics ® Data Mart database (2013-2020) and Kaplan-Meier estimators to assess risk of surgeries/reconstructions. Results: 450,803 patients were identified with an incident CSCC diagnosis, including 4111 patients with CSCC who initiated systemic therapy. The respective 7-year risks of major cutaneous surgeries/reconstructions were 10.9% (95% CI: 10.7-11.0) and 21.8% (95% CI: 17.6-25.8). Overall risk of major cutaneous surgeries/reconstructions was higher in patients who were immunocompromised than those who were immunocompetent. Conclusion: Approximately one in nine patients with CSCC will undergo ≥1 major cutaneous surgeries/reconstructions within 7 years of diagnosis; the risk increases in patients who initiate systemic therapy and among those who are immunocompromised. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|